Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Designation crawled time : 12:20 save search
NETSOL Cloud Services Achieves AWS Lambda Service Delivery Designation
Published: 2023-07-17 (Crawled : 12:20) - globenewswire.com
NTWK | $2.69 1.13% 1.12% 7.7K
|
Technology Services
|
| O: 3.62%
H: 0.0%
C: -3.49%
services service cloud designation
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
Published: 2023-06-22 (Crawled : 12:20) - globenewswire.com
KYMR | $35.7 3.93% 3.78% 440K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -4.91%
kt-253 fda drug treatment designation leukemia therapeutics
Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome
Published: 2023-01-31 (Crawled : 12:20) - prnewswire.com
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: 0.23%
H: 1.75%
C: 1.37%
fda designation fast track designation
Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
Published: 2023-01-18 (Crawled : 12:20) - globenewswire.com
KRYS | News | $162.175 3.13% 3.04% 220K
|
Health Technology
|
| O: 0.63%
H: 1.18%
C: -3.77%
kb407 treatment fibrosis designation biotech cystic fibrosis
SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors
Published: 2022-12-06 (Crawled : 12:20) - biospace.com/
SQZ | $0.435 0.0% 30M
|
Health Technology
|
| O: -9.97%
H: 0.0%
C: 0.0%
hpv16 treatment fda designation candidate sqz tumors fast track designation
Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia
Published: 2022-12-05 (Crawled : 12:20) - prnewswire.com
SNDX | $20.95 -0.05% -0.05% 870K
|
Health Technology
|
| O: -0.28%
H: 4.28%
C: 1.76%
treatment fda designation leukemia granted therapy
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease
Published: 2022-10-17 (Crawled : 12:20) - biospace.com/
MREO | $2.79 0.0% 790K
|
Health Technology
|
| O: 6.01%
H: 2.83%
C: -5.66%
treatment fda biopharma designation lung disease fast track designation alvelestat
Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors
Published: 2022-09-27 (Crawled : 12:20) - globenewswire.com
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: 10.95%
H: 8.15%
C: -20.22%
al102 fda pharmaceuticals designation granted fast track designation
Bionomics to Host KOL Webinar on BNC210 and Social Anxiety DisorderBNC210 is a First-in-Class Candidate in Clinical Development for the Acute Treatment of Social Anxiety Disorder with FDA Fast Track Designation
Published: 2022-09-21 (Crawled : 12:20) - biospace.com/
BNOX | $0.9201 -4.15% -4.33% 43K
|
n/a
|
| O: 2.66%
H: 2.72%
C: -6.36%
bnc210 treatment fda designation candidate fast track designation social anxiety disorder
Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma
Published: 2022-09-15 (Crawled : 12:20) - globenewswire.com
CADL | $5.94 7.22% 6.73% 450K
|
|
| O: 3.7%
H: 0.27%
C: -5.77%
can-2409 designation drug therapeutics
Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)
Published: 2022-08-23 (Crawled : 12:20) - biospace.com/
SYBX | $1.9 3.26% 3.16% 66K
|
Health Technology
|
| O: 0.74%
H: 6.0%
C: 1.0%
synb1353 treatment fda designation granted fast track designation
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
Published: 2022-08-11 (Crawled : 12:20) - globenewswire.com
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 1.07%
H: 2.65%
C: -3.18%
atyr1923 treatment fda designation pharma fast track designation
T2 Biosystems Receives FDA Breakthrough Device Designation for the T2Lyme Panel
Published: 2022-07-11 (Crawled : 12:20) - globenewswire.com
TTOO A | $2.725 -13.77% -15.96% 350K
|
Health Technology
|
| O: 12.63%
H: 3.76%
C: -10.33%
fda designation device
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum
Published: 2022-07-06 (Crawled : 12:20) - biospace.com/
IFRX | $1.37 0.0% 97K
|
Health Technology
|
| O: 2.82%
H: 15.75%
C: 4.79%
treatment fda designation fast track designation
US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
Published: 2022-07-06 (Crawled : 12:20) - biospace.com/
KZIA | $0.369 -2.12% -2.45% 140K
|
Health Technology
|
| O: 13.91%
H: 0.0%
C: -13.47%
fda rare designation awards disease paxalisib cancer train
Tonix Pharmaceuticals Announces Trial Design of New Phase 2 Clinical Study of TNX-1300 for Cocaine Intoxication
Published: 2022-06-27 (Crawled : 12:20) - biospace.com/
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: -9.09%
H: 1.67%
C: -1.67%
tnx-1300 trial designation phase 2
Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD
Published: 2022-06-24 (Crawled : 12:20) - globenewswire.com
ADVM | News | $10.96 -3.35% -3.47% 310K
|
Health Technology
|
| O: -0.93%
H: 3.74%
C: -0.93%
advm-022 designation granted
VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
Published: 2022-06-22 (Crawled : 12:20) - biospace.com/
VBIV | $0.591 -1.99% -2.03% 110K
|
Health Technology
|
| O: 8.21%
H: 26.11%
C: 16.65%
vbi-1901 treatment fda designation drug vaccine glioblastoma
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma
Published: 2022-06-20 (Crawled : 12:20) - contravir.com
HEPA | $1.47 4.26% 4.08% 71K
|
Health Technology
| Email alert
Add to watchlist
treatment fda designation drug
US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
Published: 2022-06-17 (Crawled : 12:20) - prnewswire.com
KZIA | $0.369 -2.12% -2.45% 140K
|
Health Technology
|
| O: 18.42%
H: 2.42%
C: -15.4%
fda rare designation awards drug cancer paxalisib train
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.